December 11, 2024 23:41 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Donald Trump vows to eliminate birthright citizenship after taking charge | No alliance with Congress in Delhi polls: AAP chief Arvind Kejriwal | Bengaluru techie's suicide: Atul Subhash's wife and her family booked | Bengaluru techie's suicide: Atul Subhash's wife and her family booked | INDIA bloc to knock on Supreme Court's doors over alleged EVM manipulation during Maharashtra polls | 'Babri Masjid should be rebuilt in Bengal's Murshidabad': TMC MLA Humayun Kabir sparks row | Rajnath Singh calls on Russian Prez Vladimir Putin in Moscow, discusses bilateral defence cooperation | Police to investigate conspiracy angle in Mumbai bus accident that killed 7 | Mamata Banerjee should lead INDIA bloc: Lalu Prasad Yadav | Opposition moves no-confidence motion against VP Jagdeep Dhankar in RS

DCGI approves DRDO's anti-COVID oral drug '2-DG' for emergency use

May 08, 2021, at 11:57 pm

New Delhi/IBNS: The Drug Controller General of India (DCGI) has approved the emergency use of DRDO's anti-COVID-19 therapeutic oral drug 2-deoxy-D-glucose (2-DG) as an adjunct therapy in moderation to severe COVID-19 patients.

India's Glenmark launches first oral antiviral drug FabiFlu to treat COVID-19 patients

Jun 21, 2020, at 01:23 pm

New Delhi/IBNS: Amid the massive spike in number of cases, India-based pharmaceutical company 'Glenmark Pharmaceuticals' has launched antiviral drug Favipiravir, to be sold under the brand name FabiFlu, for the treatment of patients having mild to moderate COVID-19 symptoms.